Newly diagnosed PAH patients on triple therapy have fewer hospitalizations vs. double therapy

PHA Canada
Feb 18, 2025
1 min read

A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an endothelin receptor agonist like ambrisentan, macitentan, or bosentan and a phosphodiesterase type 5 inhibitor like sildenafil or tadalafil) within six months had a lower risk of hospitalization and disease progression. They suggest that delaying the start of triple therapy contributes to worse outcomes.

Read the JAMA Network Open paper

Recent Posts

Promising results for drug candidate CS1

This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with d

Using sotatercept off-label in children

Clinical trials for sotatercept didn't include children, so any pediatric use is off-label. This study, conducted at one children's hospital in San Diego, evaluated sotatercept in 7 pediatric patients

Phase 1 trial of treprostinil prodrug patch succeeds

A 9-participant phase 1 clinical trial used a patch to deliver a prodrug of treprostinil (a prodrug is something that is metabolized into the drug in question inside the body). Each participant wore a

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.